Related Experiment Video
Updated: Sep 30, 2025
Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
The Multicenter Collaborative to Enhance Biologic Understanding, Quality, and Outcomes in Cardiogenic Shock (VANQUISH
Behnam N Tehrani1, Stavros G Drakos2, Filio Billia3
1Inova Fairfax Hospital, Falls Church, Virginia, USA.
Insights
The VANQUISH Shock registry aims to improve outcomes for cardiogenic shock patients by collecting comprehensive data on presentation, treatment, and quality of life. This study will enhance understanding and guide future research for better patient care.
Area of Science:
- Cardiology
- Clinical Research
- Health Outcomes
Background:
- Outcomes for cardiogenic shock (CS) remain poor despite therapeutic advancements.
- Significant gaps exist in understanding CS pathophysiology, patient phenotyping, and clinical trial design.
- There is a critical need for a comprehensive, multicenter registry to characterize CS patients.
Purpose of the Study:
- To establish the VANQUISH Shock registry, a prospective observational study.
- To characterize the contemporary presentation, treatment, and outcomes of cardiogenic shock patients.
- To assess quality of life and facilitate biomarker studies in CS.
Main Methods:
- Prospective observational registry at 4 North American centers.
- Inclusion of adult patients with primary cardiogenic shock (CS), including acute myocardial infarction (AMI-CS) and acute heart failure (HF-CS) etiologies.
- Device-agnostic approach with comprehensive data collection on clinical course, neurologic function, quality of life (QOL) using Cerebral Performance Category (CPC) and Short-Form 36 (SF-36), and serial biospecimens.
Main Results:
- Primary endpoint: survival at 30 days post-hospital discharge.
- Secondary endpoints: in-hospital adverse events, survival at 6 and 12 months.
- Longitudinal data on neurologic and health-related QOL assessments.
Conclusions:
- The VANQUISH Shock registry offers a unique platform to study CS pathophysiology and management.
- Detailed, high-quality longitudinal data will address knowledge gaps in cardiogenic shock.
- The registry will serve as a foundation for future mechanistic clinical studies to advance CS care.
Background:
Despite efforts to advance therapies in cardiogenic shock (CS), outcomes remain poor. This is likely due to several factors, including major gaps in our understanding of the pathophysiology, phenotyping of patients, and challenges with conducting adequately powered clinical studies. An unmet need exists for a comprehensive multicentre "all-comers" prospective registry to facilitate characterising contemporary presentation, treatment (in a device-agnostic fashion), and short- and intermediate-term outcomes and quality of life (QOL) of CS patients.
Methods:
The Multicenter Collaborative to Enhance Biological Understanding, Quality and Outcomes in Cardiogenic Shock (VANQUISH Shock) registry is a prospective observational registry that will study unrestricted adult patients with a primary diagnosis of CS at 4 North American centres with multidisciplinary shock programs. Both acute myocardial infarction (AMI-CS) and acute heart failure (HF-CS) etiologies will be included, and the registry will be device agnostic and widely inclusive. The primary end point will be survival at 30 days after hospital discharge. Secondary outcomes will include in-hospital adverse events and survival to 6 and 12 months. Patients will also undergo neurologic and health-related QOL assessments with the Cerebral Performance Category (CPC) and Short-Form 36 (SF-36) health survey tools before discharge and during follow-up. Serial biospecimens will facilitate biomarker studies.
Conclusions:
The VANQUISH Shock registry provides a unique opportunity to study the pathophysiology, contemporary management, clinical course, and outcomes of CS. By capturing detailed and high-quality longitudinal data, the registry will address existing knowledge gaps and serve as a springboard for future mechanistic clinical studies to advance the field.
More Related Videos
Related Concept Videos
01:24Blood Pressure Imbalances and Circulatory Shock
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:29Cardiomyopathy V: Interprofessional Care
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
01:30Cardiomyopathy II: Dilated Cardiomyopathy
01:28Acute Coronary Syndrome IV: Interprofessional Care